PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33462346-2	2021	DPYD and UGT1A1 variants are relevant predictors of fluoropyrimidine and irinotecan-associated adverse events (AEs).	2-fluoropyrimidine	52-68	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	9-15	
34996412-1	2022	BACKGROUND: Pharmacogenetic (PGx) testing for germline variants in the DPYD and UGT1A1 genes can be used to guide fluoropyrimidine and irinotecan dosing, respectively.	2-fluoropyrimidine	114-130	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	80-86	
32666389-0	2020	Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.	2-fluoropyrimidine	94-110	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	30-36	
30339275-7	2019	In patients receiving fluoropyrimidine/irinotecan, the incremental cost between DPYD variant and UGT1A1*28/*28 carriers and noncarriers was $2,975.	2-fluoropyrimidine	22-38	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	97-103	
30339275-8	2019	This study suggests that the toxicity management costs during fluoropyrimidine-based therapy are associated with DPYD and UGT1A1*28 variants and supports the utility of genotyping.	2-fluoropyrimidine	62-78	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	122-128